학술논문
PHARMACOKINETIC AND CLINICAL STUDIES WITH CEFLUPRENAM IN THE PEDIATRIC FIELD Pediatric Study Group of Cefluprenam / 小児科領域におけるCefluprenamの基礎的・臨床的総合評価
Document Type
Journal Article
Author
AKIHISA OKUMURA; AKIMASA OGAWA; AKIO HONDA; CHIKAI YASUOKA; EIICHIRO ONO; EMI HIGUCHI; FUMIKO OCHI; FUMIO HAYAKAWA; GENJU ETOH; HAJIME KIMATA; HARUHI NAKAMURA; HARUKI MIKAWA; HIDEAKI TAKAHASHI; HIDENORI MEGURO; HIROHIDE KAWASAKI; HIROHIKO HIGASHINO; HIROHISA KATOH; HIROKAZU SASAKI; HIROKI HORI; HIROKO ANDO; HIROMI OHKI; HIRONOBU AKITA; HIRONORI NAKAMURA; HIROSHI ANDO; HIROSHI MATSUDA; HISAAKI ARAKI; HITOSHI KAMIYA; ITARU TERASHIMA; IZUMI GONDO; JUN MORITA; JUNICHI YAMAMURA; JUNJI TAKAYA; KAICHI KIDA; KAORU KUBOTA; KAORU TOMINAGA; KATSUMARO AIDA; KAZUYA ITOMI; KEIKO SUEYOSHI; KEISUKE SUNAKAWA; KENJI KITAMURA; KENJI MATSUSHITA; KENTARO MATSUDA; KIMIKO TATSUMI; KIYOTAKA NAGAYAMA; KUMIKO SUGITA; KUNIYOSHI KUNO; MAKADO MATSUYUKI; MASAAKI KOBAYASHI; MASAFUMI ARAMAKI; MASAHIRO ITO; MASAO HAYASHI; MICHIO TAKAGI; MIKIYA FUJIEDA; MINAKO ETOH; MINORU KINO; MINORU SAKURAI; MITSUHARU MURASE; MIZUHO HORIKAWA; NAOICHI IWAI; NAOKI KUDA; NAOKI TSUMURA; NOBORU KAWAKAMI; NOBUO HASHIMOTO; NOBUO KOBAYASHI; RYOCHI FUJII; RYOICHI YAMAKAWA; SATOSHI IWATA; SEIKYO FURUKAWA; SHIGERU AOKI; SHIGERU IKEZAWA; SHOICHI IMAI; SHUJI YAMADA; SHUNICHI DAI; SIGEYUKI AOKI; SUGURU MATSUOKA; SUMITAKA DONO; TADAFUMI NISHIMURA; TAKANOBU KURASHIGE; TAKANORI SEKIGUCHI; TAKAO YOKOTA; TAKASHI MOTOHIRO; TAKASHI OKAMOTO; TAKASHI TOMODA; TAKASHI YAMADA; TAKASHI YAMASHITA; TAKASHIGE OKADA; TAKESHI TAJIMA; TAKESHI YUGE; TAMOTSU FUJIMOTO; TETSUYA MANABE; TOHRU IWAMURA; TOHRU KATOH; TOMOSHIGE HIRATA; TOSHIAKI ABE; TOSHIHIDE ISHIHARA; TOSHIKATSU HAYASHI; TSUNEKAZU HARUTA; YASUHIRO KURODA; YASUKO NAGAO; YASUSHI ISHIDA; YASUTAKA SAKATA; YOHNOSUKE KOBAYASHI; YOICHIRO YOSHINAGA; YOSHIKIYO TOYONAGA; YOSHIRO TSUJI; YOSHITAKE SATOH; YUJI MIYAJIMA; YUKIHIRO NODA; YUMI KAWAMURA; YUMIKO MACHIDA; YUTAKA KOBAYASHI; YUTAKA KUSUMOTO; 三河 春樹; 中村 はるひ; 中村 弘典; 久保田 薫; 久田 直樹; 久野 邦義; 今井 昌一; 伊藤 正寛; 佐々木 宏和; 佐藤 吉壮; 倉繁 隆信; 加藤 徹; 加藤 裕久; 北村 賢司; 友田 隆士; 古川 正強; 吉永 陽一郎; 堀 浩樹; 堀川 瑞穂; 堂野 純孝; 大木 洋美; 奥村 彰久; 安岡 盟; 安藤 寛; 安藤 浩子; 宮島 雄二; 富永 薫; 寺嶋 周; 小川 昭; 小林 伸雄; 小林 正明; 小林 裕; 小林 陽之助; 小野 栄一郎; 山下 貴司; 山川 良一; 山村 純一; 山田 孝; 山田 秀二; 岡本 喬; 岡田 隆滋; 岩井 直一; 岩村 透; 岩田 敏; 川上 昇; 平田 知滋; 弓削 健; 早川 文雄; 春田 恒和; 木俣 肇; 木野 稔; 末吉 圭子; 本廣 孝; 本田 明生; 杉田 久美子; 村瀬 光春; 東野 博彦; 松下 憲司; 松岡 優; 松田 健太郎; 松田 博; 松行 眞門; 林 克敏; 林 眞夫; 桜井 實; 森田 潤; 楠本 裕; 樋口 恵美; 権藤 泉; 横田 隆夫; 橋本 信男; 永山 清高; 池澤 滋; 河崎 裕英; 河村 有美; 津村 直幹; 田島 剛; 町田 裕美子; 目黒 英典; 真鍋 哲也; 石原 俊秀; 石田 也寸志; 砂川 慶介; 神谷 齊; 秋田 博伸; 糸見 和也; 臺 俊一; 荒巻 雅史; 荒木 久昭; 藤井 良知; 藤本 保; 藤枝 幹也; 衛藤 元寿; 衛藤 美奈子; 西村 忠史; 豊永 義清; 貴田 嘉一; 越智 文子; 辰巳 貴美子; 辻 芳郎; 野田 幸弘; 長尾 靖子; 間 克麿; 関口 隆憲; 阪田 保隆; 阿部 敏明; 青木 繁; 青木 繁幸; 高屋 淳二; 高木 道生; 高橋 秀明; 黒田 泰弘
Source
The Japanese Journal of Antibiotics. 1997, 50(7):597
Subject
Language
Japanese
ISSN
0368-2781
2186-5477
2186-5477
Abstract
Evaluation of efficacy and safety of cefluprenam (code number: E1077, abbreviation: CFLP), a newly developed injectable cephem antibiotics was conducted on adult patients with various infections, and followed by the study group organized from 39 institutions in pediatric field, as the drug showed no toxicity problems in suckling animals.Informed consents from legal representatives were obtained prior to the study.1. Clinical efficacyTwo-hundred eighty one cases were included for analysis of clinical efficacy after 40 cases of exclusion or drop-out were subtracted from a total of 321 cases. However, the cumulative number of cases evaluable for analysis was considered to be 289, because 8 cases that had 2 different diseases at the same time were counted in each category of disease.In the cases in which causative organisms were identified (group A), 148 of 154 cases were rated as good or excellent, with an efficacy rate of 96.1 %.As for clinical efficacies by disease, efficacy rates were 6/6 for purulent meningitis, 4/5 for sepsis, 95.7% (62/65) for pneumonia, 100.0% (29/29) for urinary tract infections, and 94.1% (16/17) for skin and soft tissue infections. The rate of excellent responses among excellent and good responses was 73.6% (109/148), showing a higher value than any of recent injectable β-lactams. On 32 cases with S. pneumoniae infection, the efficacy rate of CFLP was 100.0%. In the cases where causative organisms were not identified (group B), 128 of 135 cases were rated as good or excellent, with an efficacy rate of 94.8%. In the all cases including both the group A and the group B, the efficacy rate was 95.2% (276/289) and the rate of excellent responses among excellent and good response was 70.7% (195/276). Against severe infections, CFLP exhibited excellent clinical efficacy, showing an efficacy rate of 8/8 for meningitis, 3/5 for sepsis and 100.0% (22/22) for severe pneumonia.As for bacteriological responses, eradication rates were 95.2% (177/186) in total. Against Gram-positive cocci, the eradication rate was 92.7% (76/82), with eradication rates of 94.3% (33/35) for Staphylococcus aureus, and 93.3% (28/30) for Streptococcus pneumoniae. Against Gramnegative rods, the eradication rate was 97.1% (101/104), and eradication rates were 100.0% (22/22) for Escherichia coli, 97.5% (39/40) for Haemophilus influenzae and 100.0% (19/19) for Molaxella catarrhalis.In cases in which more than 3 days of treatment with previous chemotherapy resulted in no response, the efficacy rate of CFLP was 94.2% (98/104), rated excellent in 68 cases and good in 30 cases. In these cases, the eradication rate was 98.1% (52/53).2. PharmacokineticsCFLP was intravenously administered to 12 subjects at doses of 20 to 40 mg (potency)/kg. In 9 subjects aged more than 12 months, maximum serum levels (Cmax), T1/2β and AUC of CFLP were 155.3±9.8μg/ml, 1.43±0.18 hours and 111.7±15.0μg·hr/ml, respectively, when a dose of 20mg (potency)/kg was used. In 2 subjects aged not more than 12 months, the mean Cmax, T 1/2β and AUC were 153μg/ml, 1.6 hour and 81μgEhr/ml, respectively, at a dose of 20 mg(potency)/kg. The mean Cmax, T 1/2β and AUC were 332μg/ml, 0.93 hours and 157.3μgEhr/ml, respectively, in 1 subject at a dose of 40 mg (potency)/kg.In 10 subjects dosed 20 mg (potency)/kg, urinary levels were 2413±512, 1471±524, and 470±115μg/ml in 0-2, 2-4, and 4-6 hours after dosing, respectively, showing a cumulative urinary exeretion rate of 61.4±6.3%. In 1 subject dosed 40 mg (potency)/kg, urinary levels were 5700 and 4770μg/ml in 0-2 and 2-4 hours after dosing, respectively, showing a cumulative urinary excretion rate of 42.1%.